Simponi vs Tremfya for Ulcerative Colitis: Comparing Biologics

Simponi and Tremfya represent two very different generations of biologic therapy for moderate-to-severe ulcerative colitis. Simponi (golimumab) is a subcutaneous anti-TNF biologic that has been a UC option since 2013. Tremfya (guselkumab) is an IL-23 p19-selective biologic approved for UC in September 2024 based on QUASAR and ASTRO. Patients comparing these drugs weigh established anti-TNF mechanism against a newer class with distinctive induction flexibility. This guide walks through the simponi vs tremfya ulcerative colitis comparison.

Anti-TNF vs IL-23 p19 Mechanism

Simponi binds TNF-alpha and reduces inflammation throughout the body and in the colon. Tremfya binds the p19 subunit of interleukin-23, selectively blocking IL-23 signaling while preserving IL-12. IL-23 is a central driver of Th17-mediated inflammation in UC. The golimumab vs guselkumab distinction shapes both speed of onset and the long-term safety profile. Simponi's broader TNF blockade produces rapid systemic anti-inflammatory effects. Tremfya's selective IL-23 inhibition produces strong efficacy with a cleaner infection profile.

QUASAR and ASTRO: Tremfya UC Evidence

Simponi's UC efficacy rests on PURSUIT-SC (induction) and PURSUIT-M (maintenance). Tremfya's UC efficacy rests on QUASAR, which showed 23% clinical remission on guselkumab versus 8% on placebo at week 12, and ASTRO, which specifically evaluated fully subcutaneous induction and demonstrated that patients could skip IV induction entirely. No head-to-head trial has directly compared Simponi with Tremfya in UC. Indirect comparisons suggest Tremfya produces comparable or potentially stronger clinical remission rates.

Onset of Action

Simponi produces meaningful UC response by week 6 based on PURSUIT-SC. Tremfya's UC onset produces meaningful response by week 12 based on QUASAR. For UC patients with severe, active symptoms who need rapid control, Simponi's faster onset is often preferred. For patients in less acute states or those weighing long-term administration and safety, Tremfya's response trajectory is generally acceptable, and ASTRO's SC induction pathway allows therapy to begin without infusion center visits.

Safety and Infection Risk

Simponi carries anti-TNF class risks including serious infections, reactivation of latent TB or hepatitis B, and a small increase in lymphoma risk. Tremfya's UC safety data from QUASAR and ASTRO has been favorable, consistent with its broader psoriasis and psoriatic arthritis experience. Long-term data for IL-23 p19 biologics consistently shows lower rates of serious systemic infection than anti-TNFs. For simponi vs tremfya side effects in patients with infection concerns, cancer history, or comorbidities, Tremfya's narrower mechanism often looks more favorable. Both drugs require TB and hepatitis B screening before starting.

Administration and Dosing

Simponi for UC uses 200 mg SC at week 0, 100 mg at week 2, and then 100 mg every 4 weeks for maintenance, per Janssen's prescribing information. Simponi is all-SC throughout. Tremfya for UC offers a distinctive dual induction pathway. Patients can choose IV induction (200 mg at weeks 0, 4, and 8) or fully subcutaneous induction (400 mg at weeks 0, 4, and 8) per the QUASAR and ASTRO programs. Maintenance is 100 mg SC every 8 weeks or 200 mg SC every 4 weeks. For UC patients who want all-SC administration throughout, both drugs offer that option (Tremfya via ASTRO, Simponi throughout). Tremfya's every-8-week maintenance cadence (at the standard dose) is less frequent than Simponi's every-4-week schedule.

Anti-TNF Experienced Patients

For patients who have failed or lost response to a prior anti-TNF, a mechanism switch to Tremfya is supported by QUASAR data, which included biologic-experienced UC patients. Cycling within the anti-TNF class typically delivers lower response rates than changing mechanism classes. For UC patients with prior anti-TNF exposure, Tremfya often has better expected response.

Extraintestinal Manifestations

Simponi, as an anti-TNF, covers UC-associated extraintestinal manifestations like peripheral arthritis, ankylosing spondylitis, and certain skin conditions. Tremfya is approved for psoriasis and psoriatic arthritis through its IL-23 mechanism. For UC patients with comorbid psoriasis or psoriatic arthritis, Tremfya may offer dual benefit. For UC patients with peripheral arthritis or ankylosing spondylitis, Simponi's TNF mechanism is often preferred.

Cost and Access

Simponi's SC formulation currently lacks widely available biosimilars in the US market. Tremfya is also branded with no biosimilar. Insurance coverage varies by plan, and prior authorization is typically required for both drugs in UC. Manufacturer copay assistance programs exist for commercially insured patients on both drugs.

Choosing With Your GI

For a UC patient deciding between Simponi and Tremfya, Simponi tends to win on faster onset and extraintestinal manifestation coverage for peripheral arthritis and ankylosing spondylitis. Tremfya tends to win on long-term safety, less frequent SC maintenance (every 8 weeks vs every 4 weeks), induction flexibility (SC via ASTRO or IV via QUASAR), and performance in anti-TNF experienced patients. Ask your GI how response will be measured after induction, what to do if symptoms persist, and how your insurance handles each option. A log of stool frequency, urgency, blood, and any new extraintestinal symptoms between visits gives your care team the data to recognize early loss of response before a full flare returns.